Cocrystal Pharma, Inc. financial data

Symbol
COCP on Nasdaq
Industry
Pharmaceutical Preparations
Location
19805 N. Creek Parkway, Bothell, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
BIOZONE PHARMACEUTICALS, INC. (to 3/25/2014), International Surf Resorts, Inc. (to 3/4/2011)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 854 % -53.7%
Debt-to-equity 20.9 % +267%
Return On Equity -94.6 % -83.3%
Return On Assets -78.2 % -60.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.2M shares 0%
Common Stock, Shares, Outstanding 10.2M shares 0%
Entity Public Float 18.5M USD -51.3%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 10.2M shares +0.21%
Weighted Average Number of Shares Outstanding, Diluted 10.2M shares +0.21%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.8M USD +4.07%
General and Administrative Expense 5.55M USD -4.46%
Operating Income (Loss) -19.3M USD -5%
Nonoperating Income (Expense) 612K USD -63%
Net Income (Loss) Attributable to Parent -18.7M USD -3.78%
Earnings Per Share, Basic -1.82 USD/shares +9.45%
Earnings Per Share, Diluted -1.82 USD/shares -19.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.1M USD -44%
Assets, Current 14.3M USD -55.7%
Property, Plant and Equipment, Net 181K USD -28.2%
Operating Lease, Right-of-Use Asset 1.77M USD +1492%
Goodwill 19.1M USD 0%
Assets 16.2M USD -50.2%
Accounts Payable, Current 859K USD +51.2%
Employee-related Liabilities, Current 185K USD +6.94%
Liabilities, Current 1.95M USD +1.25%
Operating Lease, Liability, Noncurrent 1.58M USD
Liabilities 3.53M USD +83.5%
Retained Earnings (Accumulated Deficit) -330M USD -6.01%
Stockholders' Equity Attributable to Parent 12.7M USD -58.6%
Liabilities and Equity 16.2M USD -50.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.5M USD -44.7%
Net Cash Provided by (Used in) Financing Activities -7K USD -16.7%
Net Cash Provided by (Used in) Investing Activities -8K USD +82.2%
Common Stock, Shares Authorized 100M shares -33.3%
Common Stock, Shares, Issued 10.2M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.51M USD -42.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.1M USD
Deferred Tax Assets, Valuation Allowance 31.5M USD +14.3%
Deferred Tax Assets, Gross 31.9M USD +15.5%
Operating Lease, Liability 1.88M USD +1489%
Depreciation 45K USD
Payments to Acquire Property, Plant, and Equipment 8K USD -82.2%
Lessee, Operating Lease, Liability, to be Paid 2.23M USD +1758%
Property, Plant and Equipment, Gross 2.08M USD +3.33%
Operating Lease, Liability, Current 293K USD +148%
Lessee, Operating Lease, Liability, to be Paid, Year Two 419K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 407K USD +602%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 354K USD +17600%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415K USD
Deferred Tax Assets, Operating Loss Carryforwards 22M USD +2.98%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 376K USD
Operating Lease, Payments 56K USD +12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 31.5M USD +14.3%
Share-based Payment Arrangement, Expense 331K USD -37.5%
Interest Expense -220K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares